The stock of Intrexon Corp (NYSE:XON) is a huge mover today! About 634,205 shares traded hands. Intrexon Corp (NYSE:XON) has declined 21.78% since March 9, 2016 and is downtrending. It has underperformed by 29.20% the S&P500.
The move comes after 8 months negative chart setup for the $3.21 billion company. It was reported on Oct, 12 by Barchart.com. We have $25.63 PT which if reached, will make NYSE:XON worth $288.90 million less.
Analysts await Intrexon Corp (NYSE:XON) to report earnings on November, 14. They expect $-0.23 earnings per share, up 32.35% or $0.11 from last year’s $-0.34 per share. After $-0.29 actual earnings per share reported by Intrexon Corp for the previous quarter, Wall Street now forecasts -20.69% EPS growth.
Intrexon Corp (NYSE:XON) Ratings Coverage
Out of 6 analysts covering Intrexon (NYSE:XON), 4 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 67% are positive. Intrexon has been the topic of 10 analyst reports since July 27, 2015 according to StockzIntelligence Inc. The stock has “Neutral” rating given by Mizuho on Monday, January 25. The company was maintained on Monday, July 27 by Wunderlich. The rating was initiated by Stifel Nicolaus on Monday, September 21 with “Buy”. The firm has “Underperform” rating by Mizuho given on Tuesday, August 11. Wunderlich maintained Intrexon Corp (NYSE:XON) on Monday, October 19 with “Buy” rating. The stock of Intrexon Corp (NYSE:XON) earned “Neutral” rating by Mizuho on Wednesday, November 11. The firm has “Neutral” rating given on Wednesday, October 14 by Bank of America. The firm has “Market Outperform” rating given on Tuesday, May 3 by JMP Securities. The company was maintained on Tuesday, August 11 by Wunderlich. The stock of Intrexon Corp (NYSE:XON) earned “Overweight” rating by JP Morgan on Tuesday, August 11.
According to Zacks Investment Research, “Intrexon Corporation is a biotechnology company. It provides synthetic biology services. The Company designs and produces modular DNA control systems and applications for human therapeutics, protein production, industrial products, agricultural biotechnology, and animal sciences. Its technologies include the UltraVector gene design and fabrication platform; Cell Systems Informatics; LEAP-cell identification and selection, and mAbLogix-antibody discovery. Intrexon Corporation is based in Germantown, Maryland.”
Insitutional Activity: The institutional sentiment decreased to 1.12 in Q2 2016. Its down 0.22, from 1.34 in 2016Q1. The ratio is negative, as 37 funds sold all Intrexon Corp shares owned while 40 reduced positions. 18 funds bought stakes while 68 increased positions. They now own 98.85 million shares or 1.45% less from 100.31 million shares in 2016Q1.
Tiaa Cref Investment holds 165,061 shares or 0% of its portfolio. Citigroup holds 0% of its portfolio in Intrexon Corp (NYSE:XON) for 29,437 shares. Frontier Cap Management Lc holds 90,800 shares or 0.02% of its portfolio. Blackrock Gp Ltd holds 0% of its portfolio in Intrexon Corp (NYSE:XON) for 38,205 shares. Carroll Finance Associate holds 0% of its portfolio in Intrexon Corp (NYSE:XON) for 1,000 shares. Parallax Volatility Advisers Ltd Partnership accumulated 110,329 shares or 0.01% of the stock. Alliancebernstein L P holds 0% or 50,885 shares in its portfolio. Northern Tru has 232,298 shares for 0% of their US portfolio. Lagoda Mngmt L P has 4.31% invested in the company for 469,924 shares. Comml Bank Of America De accumulated 256,181 shares or 0% of the stock. Jane Street Group Incorporated Limited Company last reported 35,940 shares in the company. Delta Asset Mngmt Limited Tn has invested 0.02% of its portfolio in Intrexon Corp (NYSE:XON). Geode Cap Mngmt Limited Liability has invested 0% of its portfolio in Intrexon Corp (NYSE:XON). Stephens Inc Ar holds 0.07% or 63,453 shares in its portfolio. Swiss Natl Bank has invested 0% of its portfolio in Intrexon Corp (NYSE:XON).
Insider Transactions: Since May 13, 2016, the stock had 2 insider buys, and 0 insider sales for $1.11 million net activity. Nimrodi Nir also bought $104,484 worth of Intrexon Corp (NYSE:XON) on Monday, August 29. KIRK RANDAL J had bought 41,830 shares worth $1.00 million.
Another recent and important Intrexon Corp (NYSE:XON) news was published by Nasdaq.com which published an article titled: “Intrexon Corp Breaks Above 200-Day Moving Average – Bullish for XON” on October 03, 2016.
XON Company Profile
Intrexon Corporation (Intrexon), incorporated on June 1, 2010, forms collaborations to create biologically based products and processes using synthetic biology. The Company’s domestic activities are in California, Florida, Maryland, and Virginia, and its primary international activities are in Belgium and Hungary. The Firm designs, manufactures and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company’s technologies combine the principles of precision engineering, statistical modeling, automation and production at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing, or LEAP, and ActoBiotics platform.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.